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Abstract
Background: Needle stick injuries are a known risk in the acute hospital setting especially where the patient is 
agitated. The emotional burden on the staff experiencing this occupational injury is well reported, however there is 
insufficient data to support storing pre-filled syringes, out of the manufacturer’s pack for longer than for immediate 
administration. 
Aim: The aim was to investigate the stability and sterility of zuclopenthixol acetate and haloperidol in pre-filled 
syringes to allow their use as an alternative to drawing the dose from an ampoule or vial prior to administration.
Method: Two of the commonly used products in rapid tranquilisation were aseptically drawn in suitable syringes 
and tested for stability and sterility to establish shelf-life. Ten invited medical and nursing staff involved in rapid 
tranquilisation were invited to a focus group for feedback on the product practicality of use, cost and logistics of stock 
management.
Results: The stability and sterility tests show that zuclopenthixol acetate and haloperidol retained stability and 
sterility when stored under 25°C in a 3 mL disposable plastic syringes, for a period of 60 days with cost of AU$67 and 
AU$30 per syringe respectively.
Conclusion: The prefilled syringes provide ease and speed of administration, potential reduction in needle-stick-
injuries and proved to maintain sterility. This study demonstrated that zuclopenthixol acetate 150 mg/3mL and haloperidol 
15mg/3mL retained stability and remained sterile when stored under 2-8°C in plastic syringes for a period of 60 days. 
However the proposal was not adopted as dose flexibility was considered a greater priority than the safety gains.
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Introduction 
Needle stick injury (NSI) is a known risk in the acute hospital 
setting. While the prevalence is low in Australia [1] the emotional 
burden on health professionalsfollowingan incident is high and may 
require absence from duty and interruption to the person’s life-style 
until their safety is ensured [1]. It is also known that needlestick injuries 
are under-reported, especially from practitioners outside the public 
hospital setting [2-4], with administration and re-capping needles 
found to be the most common causes [3].
In mental health facilities, patients who require the administration 
of rapid tranquilisation medications are likely to be agitated, increasing 
the risk of needlestick injuries for the staff administering the medication, 
and the supporting staff involved in the de-escalation intervention 
or restraining the patient. The time from the decision to administer 
medication to the deliverycan be critical to patient safety. The nature of 
this procedure does not lend itself to the use of cannulation and needle-
less injection systems. The ECRI Institute [5,6] reported that 59% of 
health staff injuries from sharps are caused by needles.
The most common infections found with needlestick injuries in 
Australia were Hepatitis B, Hepatitis C and HIV [5,6]. When compared, 
the prevalence of positively diagnosed conditions was similar to the 
data from the United Kingdom and United States of America (Table 1).
The same report presented data on the direct and indirect cost of 
needle stick injuries. This included the investigation, treatment and lost 
productivity due to time off for investigations, anxiety and distress [5,6].
To gain understanding of the rapid tranquilisation (RT) process 
(calming without full sedation) and the dynamics of the situation, an 
RT administration in the hospital was attended. It was observed that the 
patient distress and the staff stress surrounding the whole process could 
easily lead to needle stick injury during the process of preparing the 
required dose. The nursing and medical staff feedback remains a crucial 
part in establishing the practicality and safety of the product.
Method
No ethical approval was required as the project involved only 
laboratory testing. 
Virus type Australia United Kingdom United States of America
Hepatitis C 1.6-40% 30% 6-30%
Hepatitis B 1.8-10% 3% 1.8%
HIV 0.1-0.3% 0.3% 0.3%
*Value of Technology: Needle stick and Sharps Injuries and Safety-Engineered 
Medical Devices[5]&[6], at: http://www.mtaa.org.au/docs/vot/vot-needlestick-and-
sharpscopytosend.pdf?sfvrsn=0.  Revised on: 22/12/13
Table 1: Needlestick Injuries and transmission risks of Hepatitis C, Hepatitis B 
and Human Immunodeficiency Virus*.
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Identifying the medications will be tested 
The most commonly used medications in rapid tranquilisations in 
this facility were midazolam, haloperidol and zuclopenthixol acetate. 
Olanzapine was sometimes used but at the time was “special access 
scheme medicine,” not approved or funded for general use in Australia. 
In addition, its form as a lyophilised powder and poor stability after 
reconstitution limited its potential in this context, accordingly it was not 
considered to be feasible. Benztropine was also used, but it was not used 
often and is used only after initial sedation to control side effects, when 
the situation has calmed. Midazolam was excluded as the Therapeutics 
Good Administration (TGA) of Australia had a previously established 
profile and identified a 60 days shelf-life, from production date, if the 
syringes were prepared in an approved Pharmaceutical Inspection 
Convention and Pharmaceutical Inspection Cooperation Scheme 
(PIC/S) clean room environment and aseptic manufacturing process. 
Accordingly haloperidol and zuclopenthixol acetate were chosen to be 
tested.
The products tested for stability were: zuclopenthixol acetate, clear 
glass single use ampule (Clopixol Accuphase™, Lundbeck Australia Pty. 
Ltd) 30 mg/3 mL and haloperidol glass single use ampule (Serenace™, 
Sigma Pharmaceuticals Pty. Ltd) 5 mg/mL, the syringes used were 
Becton, Dickinson and company™ manufactured 5 mL plastic disposable 
syringes containing a final volume of 3 mL. Storage condition of the 
original products was nominated to be 25ºC. Acquisition of all items 
required and all processes and process documentation involved in 
aseptic compounding of these products were conducted in accordance 
with PIC/S. The supplier provided the testing laboratory with one batch 
of each of the test products. Each syringe contained the exact content of 
one ampule and was directly filled from that ampule. The aseptic filling 
process was completed in an accredited clean room utilising a laminar 
flow cabinet by a validated clean room technician under supervision of 
a registered pharmacist.
Testing after the aseptic manufacturing
Two aspects were tested, stability and sterility. Stability was tested 
in the TGA’sapproved laboratories and the microbiology, sterility 
and endotoxin content were conducted in the AMS™ Laboratories 
(Silverwater Australia) (AMS). 
Stability testing TGA Laboratories
The method was designed (Table 2) by the TGA, based upon the 
methods of the British Pharmacopeia. Additional information was 
requested by the TGA to guide the development of the testing method; 
such as the desirable storage condition at the point of use in health 
facilities and frequency of use of the two products. The time stability 
trial required that:
−	 The pre-filled syringes must be filled by the selected 
manufacturer with the same commercial products as would be 
used in future production in accordance to the manufacturer’s 
validated aseptic compounding process.
−	 The syringes used in the testing process must be the same to 
that will be used in future production.
−	 If any of the batch production conditions or material changed 
the stability data would no longer be valid and new stability 
trial would be required.
Three packs of 10 syringes of each of the two products were delivered 
to the TGA laboratories and the master code, batch number and expiry 
date for the syringes were recorded on receipt. A sample identification 
code was then assigned to each product by the TGA scientists and 
stored in a temperature controlled store room under 22 ± 1ºC.
−	 In lots of five syringes of each medicine per time-point for plus 
one lot of five used as control. The pilot batch of syringes was 
produced and transported from the manufacturer to the TGA 
laboratories under the same transport conditions as to be used 
to deliver to the health facilities, and at the same temperature 
(25ºC) the product will be stored during transportation of the 
manufacturer product requirement.
−	 Haloperidol syringes were tested at weeks 1, 3, 6 and 9 after 
receipt date, and zuclopenthixol acetate syringes were tested at 
weeks 2, 4, 7 and 10 after receipt date.
−	 The products were tested to using the methods specified in the 
British Pharmacopoeia 2008 (Table 2).
Sterility testing AMS laboratories
−	 Ten syringes of each of the two products were delivered to 
the AMS laboratories under the same transport conditions 
as to be used to deliver to the health facilities, and at the 
same temperature (25ºC) the product will be stored during 
transportation of the manufacturer product requirement.
−	 A sample identification code was then assigned to each product 
by the AMS scientist and stored in a temperature controlled 
store room under 22 ± 1ºC.
−	 Appearance was noted on both samples, using a 3 mL syringe of 
each of the two products.
−	 The laboratory used the Limulus Amoebocyte Lysate (LAL) 
kinetic chromogenic method TM125 for sample validation.
Clopixol Accuphase™ zuclopenthixol acetate 150 mg/3mL 
samples were initially diluted in pyrogen-free water (PFW) with 0.5% 
Product / presentation Test / procedure Test method
Serenace™
Haloperidol 15 mg/3mL syringes for injection
Appearance Visual inspection
Content and ID of haloperidol HPLC
Related substances TLC
pH British pharmacopeia
Particulate matter (at week 9 only) British pharmacopeia
Clopixol Accuphase™ zuclopenthixol acetate 150mg/3mL
Appearance Visual inspection
Content and ID of zuclopenthixol acetate HPLC
Related substances HPLC
Colour saturation at 440 nm UV
Particulate matter (at week 10 only) British pharmacopeia
Table 2: Products tested to Pharmacopoeial specifications.
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pyrosperse (supplied by Cambrex / Lonza) and vigorously vortexed 
as a pre-treatment step. Further dilution was then made in PFW to 
investigate the inhibition and enhancement effect by spiking a known 
amount of endotoxinand testing for recovery. A dilution of 1/100 in 
PFW was shown to have a satisfactory recovery, indicating an adequate 
prevention of inhibition and enhancement by the product.
Serenace™ Haloperidol 15 mg/3 mL sample did not require a 
pre-treatment; dilutions were made in PFW to also to investigate the 
inhibition and enhancement effect by spiking a known amount of 
endotoxin and testing for recovery. Dilution of 1/100 in PFW was shown 
to have a satisfactory recovery, indicating an adequate prevention of 
inhibition and enhancement by theproduct.
After validation tests were performed the TM125 (kinetic 
chromogenic) LAL test was performed on the samples.
Results
Stability tests results
The samples met the specified physical characteristics of the two 
products as specified in the 2008 British Pharmacopeia with no changes 
or trends identified in their visual appearance. There were no changes in 
the parent products or their related substances. The particulate matter 
remained within the 2008 British Pharmacopeia range. The parent 
product remained within the British Pharmacological requirement 
(2008) ranges (95-105% for Clopixol Accuphase™ and 90-110% for 
Serenace™) with insignificant changes recorded as 2.4% and 4.2% for 
Clopixol Accuphase™ and 90-110% for Serenace™ respectively. The 
results are shown in Tables 3 and 4. Only Haloperidol required pH 
testing as indicated by the British Pharmacopeia 2008.
Sterility tests results
The results for the Kinetic Chromogenic LAL assay which 
performed to detect endotoxin units (EU)/mL was <0.5 EU/mL (Limit 
is 0.5 EU/mL) for Clopixol Accuphase™ zuclopenthixol acetate and 
Serenace™ Haloperidol 15 mg/3mL samples (Table 5).
Clopixol Accuphase™ zuclopenthixol acetate 150 mg/3mL sample 
validations for sterility was conducted and growth was recovered within 
72hours at respective incubation temperatures (Table 6) indicating that 
the sample testing procedures and specification were conducted in 
accordance with the test for sterility specified in the TM115 section 5, 
British 2008 and European Pharmacopeia 2008.
The sterility test results for Clopixol Accuphase™ zuclopenthixol 
acetate and Serenace™ Haloperidol 15 mg/3mL samples indicated no 
Time Point Test Results / Specifications
Visual appearance
Assay of zuclopenthixol 
acetate
HPLC
Related substances 
(including transisomer) 
HPLC
Colour of the solution at 
440 nm
HPLC
Particulate matter
BP method
Clear yellowish oil 95-105% Complies with BP NMT 0.2 Complies 
Week 2 Satisfactory 101.2 Complies 0.054 Complies 
Week 4 Satisfactory 100.4 Complies 0.047 Complies 
Week 7 Satisfactory 98.9 Complies 0.054 Complies 
Week 10 Satisfactory 98.8 Complies 0.056 Complies 
Table 3: Clopixol Accuphase™ zuclopenthixol acetate 150mg/3mL samples specification for stability test.
Time Point Test Results / Specifications
Visual appearance Assay of haloperidol HPLC
Related substances 
By TLC pH
Particulate matter
BP method
Clear colourless solution 90-110% Complies with BP 2.8-3.6 Complies 
Week 2 Satisfactory 102.1 Complies 3.3 Complies 
Week 4 Satisfactory 98.7 Complies 3.3 Complies 
Week 7 Satisfactory 98.5 Complies 3.4 Complies 
Week 10 Satisfactory 97.9 Complies 3.4 Complies 
Table 4: Serenace™ Haloperidol 15 mg/3mL syringes for injection samples specification for stability test.
Sample Reference LAL Assay Detection Limit Endotoxin units (EU)/mL
LAL Result
EU/mL
Serenace™
Haloperidol 15 mg/3mL syringes for injection Diluted 1/100 in PFW 0.5 <0.5
Clopixol Accuphase™ zuclopenthixol acetate 150 mg/3mL
Initial dilution of 1/10 in PFW with 0.5% pyrosperse made and vortexed. Further dilution then made to 1/100 in PFW 0.5 <0.5
Table 5: Kinetic Chromogenic LAL test results.
Test organism Strain number Media used Incubation temperature in ºC
Inoculum A (cfu/
mL)
Inoculum B (cfu/
mL) Mean  (cfu/mL)
Evaluation (growth/
no growth)
Staphylococcus aureus ATCC 6538 THO 30-35ºC 35 39 37 Growth
Pseudomonas aeruginosa ATCC 9027 THO 30-35ºC 14 17 16 Growth
Clostridium sporogenes ATCC 11437 THO 30-35ºC 43 49 46 Growth
Bacillus subtillis ATCC 6633 TO5 20-25ºC 70 85 78 Growth
Candida albicans ATCC 10231 TO5 20-25ºC 19 22 21 Growth
Aspergillus niger ATCC 16404 TO5 20-25ºC 27 34 31 Growth
Table 6: ClopixolAccuphase™ zuclopenthixol acetate 150mg/3mL and Serenace™ Haloperidol 15 mg/3mL samples validation.
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growth when treated with fluid thioglycollate USP + 0.5% tween 80 at 
30-35ºC / 14 days and tryptone Soya Broth + 0.5% Tween 80 at 20-
25ºC / 14 days (Table 7 and 8), which complies with British 2008 and 
European Pharmacopeia 2008. 
Discussion
Due to financial constraints and limitation in suitable facilities and 
equipment for aseptic dispensing and testing, the two processes were 
contracted out to accredited compounding provider and laboratories. 
The compounder the TGA good manufacturing practice guidelines 
which based on the PIC/S principles, the ISO Standards 14644.1-4 and 
13408-7:2012, the Australian standards AS 1386 – Cleanrooms and 
clean workstations for aseptic preparations.The laboratories conducting 
the testing were accredited by the National Association of Testing 
Authorities, Australia and applied the established testing methods for 
pharmaceutical products by those products manufacturers and the 
methods specified in the British Pharmacopeia 2008. This arrangement 
imposed some limitations on the possibility of repeating any testing to. 
The sample tested (Serenace™ Haloperidol 15 mg/3mL syringes, 
Clopixol Accuphase™ zuclopenthixol acetate 150 mg/3mL) for 
stability and sterility met the Pharmacopoeial requirements (British 
Pharmacopeia and European pharmacopeia 2008 edition) for 
parameters tested, during the testing period when stored below 25°C 
and protected from light. No significant changes or trends were 
observed in the stability trial for any parameters in either product. 
Particulate matter was tested and was acceptable for both products.
−	 The tested doses (Haloperidol 15 mg/3 mL, zuclopenthixol 
acetate 150 mg/3mL and Midazolam 5mg/1mL) are not the 
only doses used. 100 mg zuclopenthixol acetate, 10-20 mg 
haloperidol, and benztropine 2 mg are also used.
−	 Prefilled syringes may be of significant use in facilities with 
large number of acute cases.
−	 There may be need to use of multiple syringes or part syringe 
content, which may lead to medication administration errors. 
Nursing staff preferred to mitigate the needle stick injury risk 
themselves over taking the risk of causing medication dose or 
administration error (measuring and drawing the dose from 
the original manufacturer ampule rather than discarding the 
excess from the pre-filled syringes).
−	 The short shelf life of 60 days would lead to increased turnover 
and wastage compared to the shelf-life of the manufacturer’s 
ampoules and empty syringes, and was considered unlikely to 
be cost-effective.
Conclusion
This study demonstrated the possibility of providing a safer pre-
filled syringes product when compared to current practice in many 
mental health facilities. Filling syringes and label them with short-drug 
name or description using a wound dressing-tap rather than what we 
achieved with this study to produce appropriately labelled pre-filled 
syringes which carry shelf-life, storage details, drug name/strength/
dose and rout of administration, based on scientific finding rather than 
guessing. 
This study demonstrated that Clopixol Accuphase™ (zuclopenthixol 
acetate) 150 mg/3 mL and haloperidol 15 mg/3 mL retained stability 
and remained sterile over 10 and 9 weeks respectively when stored 
under 25°C in disposable plastic syringes for a period of 60 days, when 
tested using the British Pharmacopeia and the European Pharmacopeia 
methods and criteria (Tables 7 and 8).
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Table 7: ClopixolAccuphase™ zuclopenthixol acetate 150 mg/3mL sterility tests 
results after 60 days.
Media / Incubation
Clopixol Accuphase™ zuclopenthixol acetate 150mg/3mL
Observation
Growth / 
No growth
Fluid Thioglycollate USP+ 0.5% Tween 80 at 30-35ºC / 14 days No growth
Tryptone Soya Broth + 0.5% Tween 80 at 20-25ºC / 14 days No growth
Media / Incubation
Serenace™ Haloperidol 15 mg/3mL syringes for injection
Observation
Growth / no 
growth
Fluid Thioglycollate USP+ 0.5% Tween 80 at 30-35ºC / 14 days No growth
Tryptone Soya Broth + 0.5% Tween 80 at 20-25ºC / 14 days No growth
Table 8: Serenace™ Haloperidol 15 mg/3mL syringes for injection sterility tests 
results after 60 days.
